Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ExonHit Therapeutics has entered into an exclusive agreement with Genmab for selection of new splice variants that have the potential to be therapeutic targets for breast cancer.
Subscribe to our email newsletter
Genmab holds exclusive development and commercialisation rights on 10 events out of a breast cancer database discovered using ExonHit’s genome-wide SpliceArray technology (RNA splicing analysis platform covering the entire genome).
As per the terms of the agreement, Genmab owns first negotiation rights on other epitopes that ExonHit further characterises from this data while ExonHit retains full rights on all uses of the database.
ExonHit has used its target discovery platform that is built upon its genome-wide SpliceArray technology to identify over 2,700 RNA sequences that are expressed specifically in breast cancer tissue. These sequences are part of a database that can be analysed using workflows tailored to different target and therapeutic classes.
Loic Maurel, president of management board at ExonHit Therapeutics, said: “As already demonstrated with Allergan’s recent outlicensing deal with Bristol-Myers Squibb, our genome-wide SpliceArray platform can contribute to the development of more efficacious treatment by identifying new therapeutics targets.”